Cite

HARVARD Citation

    Kolbinger, F. et al. (n.d.). Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays. Journal of dermatological science. 84 (1), pp. e122-e123. [Online]. 
  
Back to record